MA50409A - Polythérapies pour le traitement du cancer - Google Patents

Polythérapies pour le traitement du cancer

Info

Publication number
MA50409A
MA50409A MA050409A MA50409A MA50409A MA 50409 A MA50409 A MA 50409A MA 050409 A MA050409 A MA 050409A MA 50409 A MA50409 A MA 50409A MA 50409 A MA50409 A MA 50409A
Authority
MA
Morocco
Prior art keywords
polytherapies
cancer
treatment
Prior art date
Application number
MA050409A
Other languages
English (en)
French (fr)
Inventor
Keith W Mikule
Kaiming Sun
Jing Yu Wang
Zebin Wang
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of MA50409A publication Critical patent/MA50409A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA050409A 2017-09-30 2018-09-28 Polythérapies pour le traitement du cancer MA50409A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566398P 2017-09-30 2017-09-30
US201762578298P 2017-10-27 2017-10-27
US201862654024P 2018-04-06 2018-04-06

Publications (1)

Publication Number Publication Date
MA50409A true MA50409A (fr) 2020-08-26

Family

ID=65903287

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050409A MA50409A (fr) 2017-09-30 2018-09-28 Polythérapies pour le traitement du cancer

Country Status (13)

Country Link
US (1) US11661453B2 (enExample)
EP (1) EP3697442A4 (enExample)
JP (2) JP2020536066A (enExample)
KR (1) KR20200086664A (enExample)
CN (1) CN111372607A (enExample)
AU (1) AU2018338901A1 (enExample)
BR (1) BR112020006286A2 (enExample)
CA (1) CA3076515A1 (enExample)
IL (1) IL273395A (enExample)
MA (1) MA50409A (enExample)
MX (1) MX2020003770A (enExample)
SG (1) SG11202002862RA (enExample)
WO (1) WO2019067978A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110049777A (zh) * 2016-11-01 2019-07-23 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
WO2018200517A1 (en) 2017-04-24 2018-11-01 Tesaro, Inc. Methods of manufacturing of niraparib
TW202444417A (zh) * 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
AU2019351522B2 (en) * 2018-09-29 2025-10-30 Guangzhou Burning Rock Dx Co., Ltd. Second generation sequencing-based method for detecting microsatellite stability and genome changes by means of plasma
WO2022076917A1 (en) * 2020-10-08 2022-04-14 Kumquat Biosciences Inc. Modulators of cell proliferation and uses thereof
AU2022276986B2 (en) * 2021-05-18 2025-07-03 Onconic Therapeutics Inc. Parp inhibitor-resistant cancer therapeutic agent
CN113234160B (zh) * 2021-05-26 2022-05-27 广州爱思迈生物医药科技有限公司 一种抗pd-1抗体及其应用
WO2024259248A2 (en) * 2023-06-15 2024-12-19 Memorial Sloan-Kettering Cancer Center Methods for treating cancer patients with homologous recombination deficiency based on pathognomonic long molecule footprints of backup repair pathways
KR20250087969A (ko) 2023-12-08 2025-06-17 주식회사 이앤지테크 팝업댓글 플랫폼을 활용한 소상공인 업소안내 증강현실 시스템 및 그 구동방법

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059571T3 (es) 1988-01-19 1994-11-16 Takeda Chemical Industries Ltd Fumagilina como agente angiostatico.
DE68915900T2 (de) 1988-09-01 1994-11-24 Childrens Medical Center Angiogenese hemmendes Mittel.
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US9707302B2 (en) * 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AU2008321382A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
WO2009064738A2 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
EP2240466B1 (en) 2008-01-08 2015-07-29 Merck Sharp & Dohme Limited Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
US9078864B2 (en) 2008-01-08 2015-07-14 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
AR075239A1 (es) 2009-02-04 2011-03-16 Bipar Sciences Inc Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
WO2011153383A1 (en) 2010-06-04 2011-12-08 Bipar Science, Inc. Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
EP3327148B1 (en) 2010-06-18 2021-03-17 Myriad Genetics, Inc. Methods of predicting the status of brca1 and brca2 genes in a cancer cell
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
EP2928473B1 (en) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
DK2928865T3 (en) 2012-12-07 2018-06-18 Merck Sharp & Dohme BIOCATALYTIC TRANSAMINATION PROCEDURE
WO2014138101A1 (en) 2013-03-04 2014-09-12 Board Of Regents, The University Of Texas System Gene signature to predict homologous recombination (hr) deficient cancer
US20150071910A1 (en) 2013-03-15 2015-03-12 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CA2931181C (en) 2013-12-09 2023-01-24 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
JP6663350B2 (ja) 2014-01-16 2020-03-11 クロヴィス・オンコロジー，インコーポレーテッド ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用
US20170175197A1 (en) * 2014-01-29 2017-06-22 Caris Mpi, Inc. Molecular profiling of immune modulators
JP6648040B2 (ja) 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用
US20150344968A1 (en) 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
PL3277321T3 (pl) 2015-04-01 2024-11-18 Anaptysbio, Inc. Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
WO2016176503A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
EP3303397A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
CN108883115A (zh) 2015-10-26 2018-11-23 麦迪韦逊科技有限责任公司 用parp抑制剂治疗小细胞肺癌
WO2017142871A1 (en) 2016-02-15 2017-08-24 Astrazeneca Ab Methods comprising fixed intermittent dosing of cediranib
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
US11202782B2 (en) * 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
MA50677A (fr) 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
CN110049777A (zh) 2016-11-01 2019-07-23 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
AU2018205401B2 (en) 2017-01-09 2025-01-02 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
EP3606523A1 (en) 2017-03-27 2020-02-12 Tesaro, Inc. Niraparib formulations
WO2018200517A1 (en) 2017-04-24 2018-11-01 Tesaro, Inc. Methods of manufacturing of niraparib
TWI791519B (zh) 2017-04-27 2023-02-11 美商提薩羅有限公司 針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
US20200129482A1 (en) 2017-06-26 2020-04-30 Abbvie Inc. Treatment of non-small cell lung cancer
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
TW201929902A (zh) 2017-12-27 2019-08-01 美商提薩羅有限公司 治療癌症之方法
BR112020015909A2 (pt) 2018-02-05 2020-12-15 Tesaro, Inc. Formulações pediátricas de niraparib e métodos de tratamento pediátrico
EA201992594A1 (ru) 2018-03-26 2020-03-20 Тесаро, Инк. Комбинированные терапии для лечения рака
US11970530B2 (en) 2020-08-13 2024-04-30 Astrazeneca Ab Methods of treating homologous recombination deficient cancer

Also Published As

Publication number Publication date
IL273395A (en) 2020-05-31
JP2023076826A (ja) 2023-06-02
EP3697442A1 (en) 2020-08-26
SG11202002862RA (en) 2020-04-29
CA3076515A1 (en) 2019-04-04
KR20200086664A (ko) 2020-07-17
MX2020003770A (es) 2020-07-29
AU2018338901A1 (en) 2020-05-07
CN111372607A (zh) 2020-07-03
US11661453B2 (en) 2023-05-30
US20200299387A1 (en) 2020-09-24
EP3697442A4 (en) 2021-07-07
JP2020536066A (ja) 2020-12-10
WO2019067978A1 (en) 2019-04-04
BR112020006286A2 (pt) 2020-10-20

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3431105A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OF CANCER
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3452060A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
EP3397963A4 (en) P38 MAPK INHIBITION FOR THE TREATMENT OF CANCER
EP3494142A4 (en) ANTI-SIGLEC-7 ANTIBODIES FOR TREATING CANCER
EP3432927A4 (en) TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
EP3436002A4 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER
EP3368559A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3285773A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3389645A4 (en) COMBINATIONS FOR TREATING CANCER
EP3359255A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
EP3400010A4 (en) ANTI-HER2 COMBINATIONS FOR THE TREATMENT OF TUMORS
EP3359192A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
EP3630196A4 (en) COMBINATION THERAPIES FOR TREATMENT OF CANCER
EP3490561A4 (en) COMBINATIONS FOR TREATING CANCER
EP3474854A4 (en) CANCER TREATMENT COMBINATIONS
EP3362066A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES
EP3541417A4 (en) COMBINATION IMMUNOTHERAPIES FOR TREATING CANCER
EP3331510A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
EP3503887A4 (en) COMBINATIONS FOR TREATING CANCER
EP3462883A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3347025A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT